Lupin gets EDQM nod for its Madhya Pradesh facility

US based Drug maker Lupin has received a go ahead signal from European Directorate for the Quality of Medicines (EDQM) for its Mandideep facility in Madhya Pradesh. According to Lupin, the facility inspected by EDQM in March this.

"The inspection was focused on the application for certificate of suitability for the dossier of Cefaclor along with facility inspection for Quality Management Systems based on cGMP as laid under European Union rules governing medicinal products," it added.

Lupin MD Nilesh Gupta said, "We are happy to receive the EDQM attestation for our Mandideep facility."

Lupin has continued to drive multiple initiatives over the months in the past to boost its manufacturing standards and best practices to gain its reputation, he added.

Lupin stock was trading 1.53 per cent up at Rs 827.90 on BSE in the afternoon.